MET inhibitors for treatment of advanced hepatocellular carcinoma: A review
about
Hepatobiliary Tumors: Update on Diagnosis and ManagementPathogenesis of Myeloproliferative Neoplasms: Role and Mechanisms of Chronic InflammationGlypican-3 Targeting Immunotoxins for the Treatment of Liver CancerIntegrative meta-analysis identifies microRNA-regulated networks in infantile hemangiomaTransposon mutagenesis identifies genes and cellular processes driving epithelial-mesenchymal transition in hepatocellular carcinoma.Platelet-derived growth factor receptor α in hepatocellular carcinoma is a prognostic marker independent of underlying liver cirrhosisReceptor tyrosine kinase mutations in developmental syndromes and cancer: two sides of the same coinClinical guideline SEOM: hepatocellular carcinomaMicroRNA-181b-5p, ETS1, and the c-Met pathway exacerbate the prognosis of pancreatic ductal adenocarcinoma after radiation therapy.Cabozantinib in the treatment of hepatocellular carcinoma.The Therapeutic Targeting of HGF/c-Met Signaling in Hepatocellular Carcinoma: Alternative Approaches.Targeting multiple oncogenic pathways for the treatment of hepatocellular carcinoma.Prognostic value of c-Met overexpression in hepatocellular carcinoma: a meta-analysis and review.The efficacy and safety of tivantinib in the treatment of solid tumors: a systematic review and meta-analysis.Recent developments of c-Met as a therapeutic target in hepatocellular carcinoma.Differential responses of MET activations to MET kinase inhibitor and neutralizing antibody
P2860
Q26775654-611336E9-1C23-4038-AE7F-2966AEB6F978Q26779960-86DB7E17-94F3-4739-A45E-A96764EA0646Q28077270-66072BD2-25E3-4552-AAD1-32D2A3041CCEQ29248288-3A8D6A2E-AD05-4249-89BE-74D4D504C982Q30368024-4FC0EF9D-2DC6-4AA7-AF80-EE658908CC4EQ33889261-71E77533-0464-4B2E-9C7E-14C1BC2873F1Q36065321-0EFC8F30-099E-4645-8A7B-2386DD62EB32Q36400259-95910BEA-9CC7-480C-B1A6-3022C79822CDQ37735617-2895177D-9F8E-4799-AD30-25337BA7652CQ38658285-90428172-9FBE-4BF7-8219-9196CC80799BQ38674137-FD8BE3BF-131B-4D95-8765-3F387D042F3AQ38923977-DA99D96C-C8DC-4D6E-B1EF-23015271F4CFQ47139946-8309453B-836D-4F82-BF10-39FDE70C8072Q47653274-DBCE8138-3956-4145-8DFA-D6B8FF912498Q48140297-44202F5F-9C69-42B7-80C3-A69F8B815B72Q58748732-8C4251F5-952B-4CEA-A8A8-63D841F75348
P2860
MET inhibitors for treatment of advanced hepatocellular carcinoma: A review
description
2015 nî lūn-bûn
@nan
2015 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
MET inhibitors for treatment of advanced hepatocellular carcinoma: A review
@ast
MET inhibitors for treatment of advanced hepatocellular carcinoma: A review
@en
MET inhibitors for treatment of advanced hepatocellular carcinoma: A review
@nl
type
label
MET inhibitors for treatment of advanced hepatocellular carcinoma: A review
@ast
MET inhibitors for treatment of advanced hepatocellular carcinoma: A review
@en
MET inhibitors for treatment of advanced hepatocellular carcinoma: A review
@nl
prefLabel
MET inhibitors for treatment of advanced hepatocellular carcinoma: A review
@ast
MET inhibitors for treatment of advanced hepatocellular carcinoma: A review
@en
MET inhibitors for treatment of advanced hepatocellular carcinoma: A review
@nl
P2093
P2860
P3181
P356
P1476
MET inhibitors for treatment of advanced hepatocellular carcinoma: A review
@en
P2093
Guo-Hong Han
Hong-Yu Li
Jiang Chen
Xiao-Zhong Guo
P2860
P304
P3181
P356
10.3748/WJG.V21.I18.5445
P407
P50
P577
2015-05-14T00:00:00Z